48 results about "Im injections" patented technology

The invention relates to the technical field of animal husbandry, in particular to a synchronous oestrus-timing insemination method suitable for cattle, which comprises the following steps: firstly, performing intramuscular injection of PG (cloprostenol sodium) at different time points after calving to promote uterine recovery and luteolysis and lay a synchronous oestrus foundation; the method comprises the key steps that GnRH (gonadotropin release hormone) is given through intramuscular injection on the 43rd day, the 53rd day, the 60th day and the 69th day, pituitary is promoted to release follicle-stimulating hormone (FSH) and luteinizing hormone (LH), collection and screening of follicles are guided, follicle maturation is promoted, the oestrus uncovering rate and the oestrus conception rate are increased, a melatonin implant is implanted in a subcutaneous implantation mode on the 63rd day, and the melatonin implant is implanted in a subcutaneous implantation mode on the 63rd day. The synthesis of ovarian hormones is promoted by regulating the hypothalamus-pituitary-gonad axis, the secretion of follicle cell factors and maturation promoting factors is promoted, the development of granular cells is promoted, and the maturation of oocytes is promoted. According to the method, the pregnancy rate of a double-synchronization-timing insemination scheme which is most widely used in a large-scale dairy cow breeding pasture at present can be remarkably increased, and feasible technical support is provided for success of increasing the breeding efficiency of cows.

Compounds and pharmaceutical formulations including a compound and an oil, which may be formulated for intermediate- or long-acting intramuscular injection. Methods for treating respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), coronavirus, SARS CoV-2, and other RNA virus infections in mammals.

This invention provides a modified BoNT / A for treating facial wrinkles, wherein the modified BoNT / A is administered via intramuscular injection at multiple sites on an individual's face, wherein the modified BoNT / A is administered at a unit dose of greater than 1754 pg or greater than 8000 pg per site, wherein the multiple sites are selected from: up to two sites on the corrugator supercilii muscle and one site on the depressor supercilii muscle for treating glabellar lines; up to five sites on the frontalis muscle for treating forehead wrinkles; and up to three sites on the orbicularis oculi muscle for treating lateral canthal wrinkles, wherein the total dose of modified BoNT / A administered during treatment is up to 264,000 pg (and optionally greater than 88,000 pg), and wherein the modified BoNT / A comprises a BoNT / A light chain and a translocation domain (H N The structure domain), and the BoNT / B receptor binding domain (H C (structural domain).

The present invention relates to aqueous saline solutions comprising dantrolene and optionally at least one additional active ingredient, such as botulinum neurotoxin, and their use for various therapeutic and / or aesthetic purposes. The solutions can be administered in any suitable manner, but have the advantage of being particularly well-suited for intramuscular injection.

The present application relates to a kind of cat rhinotracheitis, feline calicivirus disease, cat pancytopenia triple subunit vaccine, preparation method and its application.The present application is expressed antigen protein using CHO cell strain, and synergistic effect is combined molecular adjuvant (IL-2, GM-CSF, CpG) with MF59 nanoemulsion, molecular adjuvant composition is adsorbed on the surface of MF59 nanoemulsion, then embedded in polylactic acid-glycolic acid copolymer microsphere, mixed with triple subunit protein to form vaccine preparation.The vaccine prepared in the present application can stimulate humoral immunity and cellular immunity simultaneously by subcutaneous or intramuscular injection, significantly improve antibody titer and attack protection rate, prolong immune protection period, and reduce injection site adverse reactions.The synergistic effect of protein and molecular adjuvant and MF59 makes the vaccine superior to traditional subunit vaccine in safety, stability and immunological efficacy, and is suitable for high-efficiency prevention of three viral infectious diseases in feline.

The invention relates to the technical field of mRNA vaccine research and development, and discloses a Tp0136T cell epitope mRNA vaccine based on lipid nanoparticle delivery and application of the Tp0136T cell epitope mRNA vaccine in syphilis prevention, the vaccine contains an mRNA sequence and an LNP delivery system, the mRNA sequence contains a Tp0136T1T cell epitope coding region (amino acid L477-S486, optimized by codon), a Cap 1 structure, optimized UTR and poly (A) tails of 65-76 adenosine, and psi or m5C is used for replacing trona; the LNP is prepared from SM-102, DSPC (Distearoyl Pyrrolidone), cholesterol and DMG-PEG (Dimethyl Glycol-Polyethylene Glycol) according to a molar ratio of 50 The particle size of the vaccine is less than or equal to 150nm, PDIlt; 0.2, the Zeta potential is-5 to-15 mV, and the encapsulation efficiency is greater than or equal to 93.47%. The preparation method comprises the steps of mRNA design synthesis, mRNA-LNP preparation characterization and in-vitro expression verification, through intramuscular injection inoculation, strong Th1 type and CD8 + CTL immune response can be induced, treponema pallidum load and skin ulcer rate can be reduced, and the method can be used for syphilis prevention.

The application provides a kind of medicine composition for treating muscle and bone disease and its application, belong to medical technology field.The medicine composition includes the following weight parts components: compound angelica injection 5-10 parts, kadsura injection 5-10 parts, wild medlar injection 5-10 parts, methylcobalamin injection 5-10 parts;It can also be selectively added vitamin B1 injection, vitamin B12 injection, yellow Chinese wax injection or bone peptide injection.The composition of the application is administered by acupoint injection or intramuscular injection, utilizes the synergistic effect of multiple traditional Chinese medicine injection and western medicine injection, reaches the comprehensive treatment effect of promoting blood circulation to remove blood stasis, dispelling wind to stop pain, nerve nutrition.Clinical experiments show that the application has significant effect on lumbar disc herniation, cervical spondylosis, shoulder periarthritis, knee osteoarthritis, femoral head necrosis, osteoporosis and the like, and the total effective rate is more than 95%, with fast effect, low recurrence rate, and no hormone-related side effects, suitable for patients of all ages.

The invention discloses nucleotide of fusion protein for coding neutrophil elastase and application of the nucleotide. A nucleotide sequence for coding the fusion protein is as shown in SEQ ID NO. 8; the nucleotide sequence of mRNA (messenger ribonucleic acid) for coding the fusion protein is as shown in SEQ ID NO. 12; the fusion protein comprises an optimized human neutrophil elastase (ELANE) fragment and an optimized human alpha2-macroglobulin (A2M) fragment. The mRNA preparation which is encapsulated by the nano-lipid particles and is used for coding the wild type ELANE can achieve a tumor elimination effect only by complex intratumor injection. According to the mRNA preparation which is encapsulated by the nano-lipid particles and is used for coding the ELANE fusion protein, tumor elimination in a mouse body can be realized only through intramuscular injection administration, the operation is simpler and more convenient, and the mRNA preparation is beneficial to treatment of scattered and tiny tumor focuses in the body.

The utility model relates to the technical field of injectors, in particular to a clinical intramuscular injection universal injector which comprises an injection sleeve, a needle head arranged at one end of the injection sleeve, a piston connected to the injection sleeve in a sliding mode, a push rod with one end extending into the injection sleeve to be connected with the piston and a push head arranged at the end of the push rod. The fixed sleeve is fixed to the injection sleeve, the movable sleeve is detachably connected to the fixed sleeve, one end of each support is connected with the movable sleeve, the three supports are arranged in a triangular shape, and when two thirds of the needle head is inserted into the human body, the bottom ends of the three supports abut against the skin of the human body; according to the intramuscular injection needle, the insertion depth of the needle head can be guaranteed, the needle head can be effectively prevented from being continuously immersed into the skin in the propelling injection process, the situation that the injection position is inclined is avoided, the difficulty of clinical intramuscular injection is reduced, and the intramuscular injection effect is guaranteed.

The invention relates to a long-acting sustained-release pharmaceutical preparation and a preparation method thereof, the long-acting sustained-release pharmaceutical preparation is a microsphere preparation, the microsphere comprises brexpiprazole and PLGA, the content of the brexpiprazole is 45%-75% of the total weight of the microsphere, and the content of the PLGA is 55%-25% of the total weight of the microsphere; the viscosity of the PLGA is 0.15 to 0.25 dl / g, and the molecular weight of the PLGA is 8000 to 32000. The microsphere is high in drug loading capacity, the administration dosage can be effectively reduced, subcutaneous or muscle administration pain of a patient is reduced, the prepared sustained-release microsphere has no burst release phenomenon, and the change of the blood concentration in an effective release period in a rat is stable.

The utility model relates to an efficient poultry vaccine intramuscular injection device which comprises an obliquely-arranged stepping support and a PLC, an injection device and a propelling device are arranged on the front end face of the stepping support, one end of the injection device is connected with the propelling device, a neck fixing device is arranged at one end of the stepping support, and the other end of the stepping support is connected with the PLC. The neck fixing device comprises a first connecting piece, a second connecting piece and a neck fixing frame arranged on the first connecting piece, the second connecting piece is connected with the stepping support, the bottom end of the second connecting piece is hinged to the first connecting piece, a proximity switch is arranged on the second connecting piece, and the neck fixing frame is connected with the neck fixing frame in a non-external force state. One side of the top end face of the hinged first connecting piece is attached to the inner wall of the second connecting piece, the proximity switch is far away from the side edge of the first connecting piece, the side edge of the first connecting piece abuts against the proximity switch in the state that the first connecting piece is lifted upwards under external force, and through the arrangement of the proximity switch, the advantages of being high in injection efficiency and low in cost are achieved.

Self-administered pharmaceutical compositions of epinephrine and its prodrugs are described as having pharmacokinetic parameters that are comparable to those compositions administered by a health care professional and by intramuscular injection.

The present invention relates to an apparatus for administering fluids intramuscularly containing a syringe with an injectable fluid and comprising a casing (1), protection means for protecting the needle (2) of the syringe, a spring (6) and displacement means for displacing the skin in a direction substantially perpendicular to the path of penetration of the needle (2). The apparatus improves procedural efficiency regardless of the user's dexterity, prevents the inoculated fluid from leaking from the injection site, and reduces or eliminates pain and the risk caused by accidental pricks with a needle. The apparatus is suitable for use in sectors involving the design, manufacture, production or use of health-related devices. Specifically, the apparatus is particularly suited for use in hospitals, clinics, prisons, elderly nursing homes, vaccination campaigns, emergency situations, etc., and, in general, where it is necessary to apply therapies with intramuscular injections.

The invention discloses preparation and application of a nucleotide and nucleotide derivative bridged lipid nucleic acid delivery system, and belongs to the technical field of biological medicine. The nucleotide and nucleotide derivative bridged lipid nucleic acid delivery system is composed of lipid nanoparticles, a nucleic acid drug and nucleotide / nucleoside / base / ribose / deoxyribose, exogenous nucleotide components are tightly combined with the nucleic acid drug through hydrogen-bond interaction and base stacking force, the stability and translation efficiency of mRNA are enhanced, and the delivery effect of the nucleotide and nucleotide derivative bridged lipid nucleic acid delivery system is improved. And then loading the two into the lipid nano-particles through electrostatic interaction. The delivery system has significant advantages in improving the entrapment efficiency, stability, transfection efficiency and cell survival rate of nucleic acid drugs, can be delivered through intravenous administration, intramuscular injection, aerosol inhalation and the like, can significantly improve the disease treatment efficiency, and has wide clinical application prospects.

The present invention belongs to the technical field of cancer immunotherapy and specifically relates to a combination-therapy drug and composition of a cholesterolylated TLR7 liposome and a TLR9 agonist and use thereof. Toll-like receptor agonists have poor targeting capability and significant side effects in anti-tumor treatment, and, as monotherapy in anti-tumor treatment, have limited efficacy. To address the described issues, the present invention provides the cholesterolylated TLR7 liposome, which is prepared from the cholesterol-modified 1V209 molecule 1V209-Cho, a lipid component, and cholesterol, and uses the liposome in combination with the TLR9 agonist to treat tumors. Animal results show that the combination of the liposome and the TLR9 agonist, when administered as nasal drops or by means of intramuscular injection, can significantly inhibit pulmonary metastasis of cervical cancer cells and melanoma cells, indicating that using the cholesterolylated liposome 1V209-Cho-Lip in combination with the TLR9 agonist to treat tumors is a strategy with great potential.

The invention relates to a compound emulsion for preventing and controlling bovine viral diarrhea. Every 100 g of the compound emulsion comprises the following components by weight: 0.1 to 6.0 g of bovine viral diarrhea antibody, 2.0 to 4.0 g of solanum nigrum polysaccharide, 0.1 to 1.0 g of donaxine, 0.1 to 5.0 g of taurine, 1.0 to 3.0 g of ephedra oil, 4.0 to 10.0 g of polyoxyethylene (40) castor oil, 10.0 to 18.0 g of linoleic acid, 14.0 to 20.0 g of ethyl oleate, 15.0 to 25.0 g of span-40, and the balance of water for injection. Primary emulsion of the reemulsion is in an oil-in-water (O / W) type, and secondary emulsion of the reemulsion is in an oil-water mutual wrapping type. The invention further discloses a preparation method, the process controllability is high, and low-cost production is facilitated. The reemulsion can play a slow-release and long-acting role after intramuscular injection, the effective concentration of the antibody can be maintained in vivo for a long time, repeated medication is not needed, the stress reaction of animals is reduced, meanwhile, viruses are neutralized more thoroughly, the overall curative effect is remarkably improved, and the treatment cycle is shortened.

This invention discloses a macromolecular JAK inhibitor, its preparation method, and its applications. This macromolecular JAK inhibitor is an anti-inflammatory amphiphilic polymer of hexachlorocyclotriphosphazene or cyanuric chloride coupled with different functional groups. The anti-inflammatory amphiphilic polymer is synthesized with hexachlorocyclotriphosphazene or cyanuric chloride as the backbone structure, linked by a stepwise nucleophilic substitution reaction with different proportions of hydrophilic modules polyethylene glycol and 3-aminobenzoyl hydrazide (i.e., luminol). The preparation method of this type of anti-inflammatory macromolecular drug is simple, its structure and function are controllable, and it is easy to synthesize on a large scale. Furthermore, this type of amphiphilic anti-inflammatory macromolecular drug can self-assemble into nanomicelles in aqueous solution through intermolecular interactions. It can be applied to the treatment of various acute and chronic inflammations or diseases related to the JAK signaling pathway, and can be administered via intravenous injection, subcutaneous injection, nebulized inhalation, intramuscular injection, and any combination of the above methods. This anti-inflammatory macromolecular drug has significant therapeutic effects in acute lung injury, acute kidney injury, acute liver failure, sepsis, and asthma.

The invention relates to the technical field of genetic engineering, in particular to a pasteurella multocida waaF gene and application thereof in attenuated live vaccines. The sequence of the pasteurella multocida waaF gene is as shown in SEQ ID NO: 1, and a delta waaF gene mutant strain is highly attenuated on ducks, has a certain in-vivo colonization level and has the potential of attenuated live vaccines. The mutant strain is immunized through oral administration and intramuscular injection, so that the production performance of ducks cannot be influenced, and 81.25% and 75% of immune protection can be provided for attacking toxic substances in the lethal dose of pasteurella multocida respectively. Compared with a delta grcA attenuated strain reported in the prior art, the delta waaF mutant strain shows higher-amplitude toxicity reduction, and shows more excellent safety and balanced immune effect only at the cost of a slightly low immune protection rate.

The invention belongs to the technical field of medicinal chemistry, and relates to a novel pamoate crystal form of xanthomeline or a deuterated substance thereof, a preparation method of the crystal form and application of the crystal form in the field of medicine. Specifically, the invention relates to two novel crystal forms B3 and E of xanthomerin pamoate as shown in a formula I and a novel crystal form d-B3 of deuterated xanthomerin pamoate as shown in a formula II. Wherein the crystal form B3 has good physical and chemical stability, can maintain an effective concentration for a long time in vivo on the premise of keeping the crystal form unchanged, and has a good patent medicine prospect, and the toxic and side effects of the medicine are obviously improved. The expected sustained-release effect can be achieved by applying the crystal form provided by the invention through different administration routes (such as intramuscular injection, subcutaneous injection, oral administration and the like). In addition, the preparation process of the crystal form is simple, the difference between batches is small, and the crystal form is suitable for industrial production.

The present application provides an amide compound and a use thereof. The amide compound is selected from a compound represented by formula (I), a tautomer thereof, a mesomer thereof, a racemate thereof, an enantiomer thereof, a diastereomer thereof, an atropisomer thereof, or a pharmaceutically acceptable salt thereof. In the present application, a series of novel amide compounds is developed. These amide compounds have excellent anti-HIV activity, no significant cytotoxicity, relatively strong affinity for HIV-1 capsid protein, and good specificity, are suitable for intravenous administration, oral administration, subcutaneous administration, and intramuscular injection administration, and show relatively long half-life and relatively high exposure in vivo. In addition, the amide compounds have no significant inhibitory effect on various CYP enzymes, exhibit high plasma protein binding, and have excellent safety and good metabolic stability in vivo, no potential off-target effect, high safety, and the potential to be developed into clinical long-acting drugs.

The invention belongs to the technical field of biology, and discloses an application of Compound C in inhibition of uterine contraction of sheep, the Compound C significantly reduces expression of autophagy related genes LC3, BECN1, ATG5 and ATG7 by regulating an AMPK / mTOR signal channel, further inhibits autophagy of sheep uterine smooth muscle cells, and realizes targeted inhibition of uterine contraction. The optimal concentration of the Compound C in the preparation is 10 <-6 > mol / L, the administration dosage is 0.01 mg / kg of sheep body weight, the administration mode is intramuscular injection, and the Compound C can be combined with oxytocin to reverse the uterine contraction promoting effect of oxytocin. Cell experiments and animal experiments prove that the Compound C can improve uterine smooth muscle cell ultramicrostructure disorder, reduce autophagosome formation, delay the recovery speed of uterine horn of postpartum sheep, effectively inhibit abnormal uterine contraction and provide a new strategy for pregnancy maintenance and abortion reduction, and the action is milder.

The invention discloses an antioxidant-free kanamycin injection and a preparation method thereof.The injection is composed of kanamycin sulfate, a pH regulator and water for injection, the pH is 4.5-7.0, headspace oxygen is controlled to be smaller than or equal to 1% through nitrogen charging, and the injection is completely free of sodium hydrogen sulfite, cysteine hydrochloride and other antioxidants and can be used for intravenous drip and intramuscular injection; the invention further provides a preparation process and an ion chromatography verification method which are compatible with an existing production line, and the product quality meets the requirements of Chinese Pharmacopoeia 2020 through high temperature, strong light and long-term stability test verification; clinical retrospective analysis shows that the rash occurrence rate is reduced to 3.1% from 27.3%, the safety is remarkably improved while the medicine quality is ensured, and the method has a good industrial application prospect.

The application discloses a preparation method of rabies virus glycoprotein and application thereof, and belongs to the technical field of biological medicines, and comprises the following steps: expressing a glycoprotein G gene of rabies virus containing an extramembrane region, a transmembrane region and an intramembrane region in yeast; performing cell disruption on the yeast, adding a detergent, and obtaining a solution containing rabies virus glycoprotein G; purifying the solution to obtain full-length rabies virus glycoprotein G; and immunizing the prepared full-length rabies virus glycoprotein G through intramuscular injection, oral administration or atomization inhalation. The scheme provided by the application has the advantages of strong immunogenicity, high safety, low production cost and easiness in scaling, solves the problems of complex traditional vaccine process and high cost, and provides a reliable new type of subunit vaccine solution for rabies prevention.

The present application relates to the field of pharmaceutical preparations, in particular to a rilugolimab long-acting microcrystalline pharmaceutical composition and a preparation method thereof, wherein a specific recrystallization process is used for rilugolimab raw materials, and the obtained crystals have uniform relative particle size and good crystal habit morphology. The rilugolimab long-acting microcrystalline pharmaceutical composition is administered by intramuscular injection, and can be sustained in vivo for at least more than 1 month, or more than 2 months, more than 3 months, or even more than 4 months, thereby effectively reducing the administration frequency, maintaining stable blood drug concentration, improving clinical efficacy, and better meeting the clinical needs.

The present invention relates to aqueous saline solutions comprising dantrolene and optionally also at least one additional active principle, such as botulinum neurotoxin, and their use for various therapeutic and / or aesthetic purposes. The solutions can be administered in any suitable way, but are advantageous in that they are particularly well adapted to intramuscular injection.

FIELD: medicine.SUBSTANCE: invention relates to simulators for practicing skills of applying surgical sutures to the skin and techniques of tying surgical knots. The simulator includes a multi-layer cushion simulating human tissues, a simulation of vessels in the tissues, and has a rectangular shape with rounded edges measuring 20 by 15 cm and a height of 1.8 cm. The simulator is made of hypoallergenic polymers and contains four layers simulating human tissues - epidermis, dermis, subcutaneous fat, muscles. Vessels of various diameters, filled with a liquid imitating blood, run in the subcutaneous layer. A flap of PVC artificial leather having a skin texture, treated with liquid release wax IZHWAX SP, is placed on a platform with legs measuring 25 by 20 cm. A part in the form of a side 1.75 mm high, printed on a 3D printer, is placed on the flap. A nylon stretch mesh with a density of 110 g / m2 is stretched over the part. The stretch mesh is fixed to the platform with clamps. A part in the form of an outer side with 'ears' 17 mm high, printed on a 3D printer, is installed on the mesh. The entire structure is completely pressed against the base using clamps so that the nylon mesh remains stretched. Platinum silicone rubber of appropriate parameters is poured into a separate container. The components are mixed and coloured with a dye for epoxy resin, and after the last layer hardens, all the existing 3D-printed sides and other parts are separated. The excess stretch mesh is cut off.EFFECT: possibility of performing training of intramuscular injection, layer-by-layer dissection of the simulator layers with a scalpel down to the underlying layers and applying sutures in hard-to-reach places, in particular on the muscle layer, fascia, aponeurosis.1 cl, 1 dwg

The present disclosure belongs to the technical field of medicinal chemistry, and relates to novel crystal forms of xanomeline pamoate or deuterated xanomeline pamoate, a preparation method therefor, and the use thereof in the field of medicine. The present disclosure particularly relates to two novel crystal forms B3 and E of xanomeline pamoate represented by formula I and a novel crystal form d-B3 of deuterated xanomeline pamoate represented by formula II. The crystal form B3 exhibits good physical and chemical stabilities, can maintain an effective concentration for long time in vivo while maintaining the crystal form unchanged, has obviously relieved medicinal toxicity and side effects and possesses good druggability. Applying the crystal forms of the present disclosure by various routes of administration (e.g. intramuscular injection, subcutaneous injection, oral administration, etc.) can all achieve an expected sustained-release effect. Furthermore, the crystal forms of the present disclosure involve a simple preparation process and have a small inter-batch difference and thus are suitable for industrial production.

The invention provides a multifunctional antigen and adjuvant co-delivered virus mimic vaccine and a preparation method thereof. The vaccine is composed of a spherical nanogel core containing CpG nucleic acid and a bionic virus spike structure outer layer, the core structure is formed by self-assembly of a Y-type nucleic acid scaffold containing a TLR9 agonist and a linear connector through base complementation, the outer layer is RBD antigen and polyarginine fusion protein, and non-covalent wrapping is achieved through a salt bridge zipper mechanism. The vaccine can efficiently enter lymph nodes through intramuscular injection, activate innate immunity and adaptive immune response and induce strong antigen-specific immune response, has the advantages of improving immunogenicity, enhancing immune effect, being strong in stability and the like, is suitable for solving the problem of poor immune effect of subunit vaccines, and has a wide application prospect.

The present invention relates to the use of modified BoNT / A for the treatment of cervical dyskinesia, including modified botulinum neurotoxin A (BoNT / A) for use in the treatment of cervical dyskinesia wherein the modified BoNT / A is administered by intramuscular injection to affected neck muscles of a subject wherein the modified BoNT / A is administered in a unit dose of 750 pg to 17,000 pg of the modified BoNT / A, wherein at least a single unit dose is administered to the affected neck muscle wherein the total dose administered during treatment is at most 170,000 pg of the modified BoNT / A, and wherein the modified BoNT / A comprises a BoNT / A light chain and a translocation domain, and a BoNT / B receptor binding domain (HC domain). Related methods, uses, unit dosage forms, and kits are also provided.

Methods of treating an allergic symptom by oral administration of epinephrine and its prodrugs are described as having pharmacokinetic parameters that are improved or comparable to those compositions administered by intramuscular injection.